Press releases

June 22, 2020

BERG Announces Presentation Of Multiple Interrogative Biology Platform® And Outputs From Multiple Collaborations At AACR

News provided by BERG Health Jun 22, 2020, 09:00 ET FRAMINGHAM, Mass., June 22, 2020 /PRNewswire/ — BERG, a clinical-stage biotech that employs artificial intelligence (AI) to research diseases and develop innovative treatments, today announced five presentations...

June 17, 2020

BERG Creates New Drug Research Effort to Use Oak Ridge National Laboratory’s Summit Supercomputer in the Fight Against COVID-19

Team Will Accelerate and Transform COVID-19 Drug Discovery Process NEWS PROVIDED BY BERG  June 17, 2020, 09:00 ET FRAMINGHAM, Mass., June 17, 2020 /PRNewswire/ — BERG, a clinical-stage biotech company that uses artificial intelligence (AI) to research...

June 1, 2020

BERG Presents Results of Phase 1 Clinical Study in Glioblastoma at 2020 American Society of Clinical Oncology (ASCO) Meeting

Study Demonstrates Safety and Tolerability and its Potential Impact on Metabolism to Elicit Anti-Cancer Response in Brain Cancer NEWS PROVIDED BY BERG  Jun 01, 2020, 09:05 ET FRAMINGHAM, Mass., June 1, 2020 /PRNewswire/ — BERG, a clinical-stage...

May 6, 2020

BERG Forms Research Collaboration With Boehringer Ingelheim To Identify Candidate Biomarkers For A Group Of Inflammatory Conditions

BERG will pair its Interrogative Biology® Platform with Boehringer Ingelheim’s Translational Medicine and Biomarker Expertise News provided by BERG Health May 06, 2020, 09:00 ET   FRAMINGHAM, Mass., May 6, 2020 /PRNewswire/ — BERG, a clinical-stage...

April 13, 2020

BERG Named Visionary in Frost & Sullivan’s First-Ever Frost Radar™ AI in Drug Discovery Report in the Pharmaceutical Industry

BERG, a clinical-stage biotech company that uses artificial intelligence (AI) to research diseases and develop innovative treatments, has been awarded a spot in Frost & Sullivan’s first-ever Frost Radar™ AI in Drug Discovery report in the pharmaceutical...

February 27, 2020

BERG Files Patent Application For First In Class Small Molecule Modulators Of A Novel Target Identified By BERG’s Interrogative Biology® Platform

Ubiquitin Conjugating Enzyme (E2) serves as key target to BERG’s oncology therapeutics discovery efforts NEWS PROVIDED BY BERG  February 27, 14:00 ET FRAMINGHAM, Mass., Feb. 27, 2020 /PRNewswire/ — BERG, a clinical stage biopharmaceutical company that...

February 14, 2020

BERG Presents Data Demonstrating That BPM31510 Promotes Cytotoxic T-cell Function And Influences Checkpoint Receptor Expression Patterns To Potentially Synergize Anti-Cancer Effect In Combination With I/O Therapies

In vivo and ex vivo studies of BPM31510 show its role promoting cytotoxic T-cell function and reversing indices of T-cell exhaustion and immunosuppression NEWS PROVIDED BY BERG  Nov 08, 2019, 07:00 ET FRAMINGHAM, Mass., Nov. 8,...

January 29, 2020

BERG Presents Initial Clinical Data And Identification Of Response Biomarkers In A Phase 2 Pancreatic Cancer Trial Guided By Using The Interrogative Biology® Platform At ASCO-GI Meeting

BERG Presents Clinical Target Validation Data for the Treatment of Parkinson’s Disease and Novel Mechanism of Action in Neurological Disorders at Neuroscience 2018 NEWS PROVIDED BY BERG  January 24, 2020 18:52 ET SHARE THIS ARTICLE FRAMINGHAM,...

October 22, 2019

BERG Collaboration Identifies Novel Mechanism Of Action Of Redox Regulation By BPM 31510 In Models Of Glioblastoma

In vivo and in vitro studies of BPM 31510 demonstrate its effect on the survival of preclinical glioblastoma models through the induction of oxidative stress NEWS PROVIDED BY BERG  October 22, 2019, 07:00 ET FRAMINGHAM, Mass., Oct....

September 28, 2019

BERG PRESENTS FIRST-IN-KIND DATA USING ITS BAYESIAN AI-DRIVEN INTERROGATIVE BIOLOGY® TECHNOLOGY TO MAP UNDERLYING BIOLOGY OF PATIENT RESPONSES IN ADVANCED SOLID TUMOR TRIAL OF BPM31510

Early phase study of BPM31510 demonstrates BERG’s Interrogative Biology® platform can identify the molecular basis of efficacy and adverse events, offering critical insights for drug late- stage development from analyses of longitudinal patient samples. NEWS PROVIDED...

June 3, 2019

BERG Presents Key Findings From Two Important Clinical Initiatives At The 2019 ASCO Annual Meeting: BERG’s Final Phase 1 Results For BPM 31543 In Chemotherapy-Induced Alopecia And A Clinical Study Using BERG’s Interrogative Biology® Platform Demonstrating The Importance Of Altruism In Pancreatic Cancer Biomarker Discovery

BERG Presents Key Findings From Two Important Clinical Initiatives At The 2019 ASCO Annual Meeting NEWS PROVIDED BY BERG  Jun 03, 2019, 11:29 ET BOSTON, June 3, 2019 /PRNewswire/ — BERG, a biopharmaceutical company that merges...

March 29, 2019

BERG ANNOUNCES DATA PRESENTATIONS AT AACR 2019 DEMONSTRATING EFFICACY OF BPM 31510 IN GLIOBLASTOMA AND IDENTIFICATION OF NOVEL PROSTATE AND PANCREATIC CANCER BIOMARKERS

NEWS PROVIDED BY BERG  March 29, 2019 BERG, biopharmaceutical company, that combines biology and technology to elucidate underlying mechanisms of disease, today announced the presentation of 4 posters at the American Association for Cancer Research (AACR)...

November 7, 2018

PRNewswire: BERG Presents Clinical Target Validation Data for the Treatment of Parkinson’s Disease and Novel Mechanism of Action in Neurological Disorders at Neuroscience 2018

BERG Presents Clinical Target Validation Data for the Treatment of Parkinson’s Disease and Novel Mechanism of Action in Neurological Disorders at Neuroscience 2018 NEWS PROVIDED BY BERG  Nov 07, 2018, 18:43 ET SHARE THIS ARTICLE BOSTON, Nov....

November 2, 2018

PRNewswire: Berg Analytics to Present at the AMIA 2018 Annual Symposium

Berg Analytics to Present at the AMIA 2018 Annual Symposium NEWS PROVIDED BY BERG  Nov 02, 2018, 07:04 ET BOSTON, Nov. 2, 2018 /PRNewswire/ — Berg Analytics, a division of BERG LLC, a Boston-based biopharmaceutical company that merges biology...

October 19, 2018

PRNewswire: BERG to Present New Data Describing Details on Progress of its Oncology Portfolio and Precision Medicine Applications at the European Society for Medical Oncology 2018 Congress

BERG to Present New Data Describing Details on Progress of its Oncology Portfolio and Precision Medicine Applications at the European Society for Medical Oncology 2018 Congress NEWS PROVIDED BY BERG  Oct 19, 2018, 18:49 ET SHARE...

June 4, 2018

BERG Showcases New Clinical Data on BPM 31510 at ASCO 2018

BERG Showcases New Clinical Data on BPM 31510 at ASCO 2018 NEWS PROVIDED BY BERG  Jun 04, 2018, 04:53 ET SHARE THIS ARTICLE BOSTON, June 4, 2018 /PRNewswire/ — BERG, LLC, a Boston-based biopharmaceutical company that merges biology with...

May 23, 2018

BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa

BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa NEWS PROVIDED BY BERG  May 23, 2018, 07:34 ET SHARE THIS ARTICLE BOSTON, May 23, 2018 /PRNewswire/ — BERG, LLC, a Boston-based biopharmaceutical...

May 23, 2018

BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa

BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa NEWS PROVIDED BY BERG  May 23, 2018, 07:34 ET BOSTON, May 23, 2018 /PRNewswire/ — BERG, LLC, a Boston-based biopharmaceutical company that merges...

April 18, 2018

BERG Announces Data Presentations at AACR 2018 Validating Novel Prostate Cancer Biomarkers and Clinical Activity of BPM 31510 Across Several Metabolic Cancer Types

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the presentation of 10 abstracts describing progress on translational preclinical data on display at the American Association for Cancer...

April 4, 2018

BERG Announces the Dosing of First UK Patient in Phase II Combination Trial of BPM 31510 and Gemcitabine for Patients with Pancreatic Cancer

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the dosing of the first patient in the United Kingdom (UK) for its Phase II pancreatic cancer clinical trial...

January 22, 2018

BERG Announces FDA Orphan-Drug Designation of BPM31510 for the Treatment of Pancreatic Cancer

BERG, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the Company’s leading product candidate BPM31510,...

BERG in the News!

BERG is making headlines.  Click here to see the latest breaking news, interviews, and press releases.